Key result
Levosimendan increases contractility without raising mortality in acute and advanced HF, retaining efficacy alongside beta-blockers.
Why the study?
Acute and advanced heart failure carry poor short- and longer-term prognoses requiring complex therapies to restore haemodynamic balance and perfusion, prompting a summary of the role of levosimendan.
Does levosimendan provide safe and effective haemodynamic support in patients with acute and advanced heart failure?
Design
Expert perspective summarizing 12 congress tutorials
Authors
Loading...
Supports levosimendan consideration in beta-blocked acute HF; leaves open confirmatory RCTs on renal and mortality effects.
Does levosimendan provide safe and effective haemodynamic support in patients with acute and advanced heart failure?
Levosimendan offers a favorable haemodynamic and safety profile for patients with acute and advanced heart failure, particularly those on beta-blockers, supporting its intermittent use.
Agostoni et al. (2019) conducted a review in Acute and advanced heart failure. Levosimendan vs. Conventional adrenergic inotropes was evaluated. Levosimendan is well suited for acute and advanced heart failure as it increases cardiac contractility without increasing mortality risk and retains efficacy in the presence of beta-blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: